SI-BONE Inc
NASDAQ:SIBN
SI-BONE Inc
Cash & Cash Equivalents
SI-BONE Inc
Cash & Cash Equivalents Peer Comparison
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
SI-BONE Inc
NASDAQ:SIBN
|
Cash & Cash Equivalents
$32m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash & Cash Equivalents
$2.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
76%
|
CAGR 10-Years
28%
|
|
Stryker Corp
NYSE:SYK
|
Cash & Cash Equivalents
$2.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
Abbott Laboratories
NYSE:ABT
|
Cash & Cash Equivalents
$6.3B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash & Cash Equivalents
$2.8B
|
CAGR 3-Years
27%
|
CAGR 5-Years
27%
|
CAGR 10-Years
13%
|
|
Shockwave Medical Inc
NASDAQ:SWAV
|
Cash & Cash Equivalents
$281.7m
|
CAGR 3-Years
70%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
See Also
What is SI-BONE Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
32m
USD
Based on the financial report for Mar 31, 2024, SI-BONE Inc's Cash & Cash Equivalents amounts to 32m USD.
What is SI-BONE Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
21%
Over the last year, the Cash & Cash Equivalents growth was 39%. The average annual Cash & Cash Equivalents growth rates for SI-BONE Inc have been -5% over the past three years , 21% over the past five years .